Lumexa Imaging (NASDAQ:LMRI) Stock Price Up 12.2% – What’s Next?

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI)’s stock price traded up 12.2% during trading on Wednesday. The company traded as high as $12.29 and last traded at $12.5850. Approximately 281,442 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 678,442 shares. The stock had previously closed at $11.22.

Analysts Set New Price Targets

LMRI has been the topic of several research reports. Barclays raised their price objective on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Raymond James Financial set a $17.00 target price on shares of Lumexa Imaging in a research report on Monday, September 28th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Lumexa Imaging in a research note on Thursday, August 13th. KeyCorp initiated coverage on Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price target on the stock. Finally, UBS Group reaffirmed a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $16.40.

Lumexa Imaging Stock Up 14.9%

The stock has a market capitalization of $1.24 billion and a P/E ratio of -26.39. The stock has a 50 day moving average price of $11.07 and a 200-day moving average price of $11.11. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44.

Lumexa Imaging (NASDAQ:LMRI) last issued its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17. The company had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, research analysts expect that Lumexa Imaging Holdings, Inc. will post 0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Lumexa Imaging

A number of large investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in shares of Lumexa Imaging during the 3rd quarter valued at $132,000. Brooklands Fund Management Ltd bought a new position in shares of Lumexa Imaging in the 3rd quarter worth about $21,577,000. State of Alaska Department of Revenue purchased a new position in Lumexa Imaging during the 3rd quarter valued at about $46,000. Squarepoint Ops LLC lifted its position in Lumexa Imaging by 506.9% during the 2nd quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock valued at $902,000 after acquiring an additional 66,763 shares during the period. Finally, Readystate Asset Management LP boosted its stake in Lumexa Imaging by 11.5% during the second quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock worth $2,826,000 after acquiring an additional 25,778 shares in the last quarter.

About Lumexa Imaging

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.